

Prof. Dr. med. Barbara F. Eichhorst

Scientific Curriculum

Academic Career:

- 01/2020 Personell senior physician
- 07/2019 Adjunct Professor at the University of Cologne
- 12/2011 Habilitation and granted *venia legendi* for the subject Internal Medicine
by Medical Faculty of the University of Cologne
„ Treatment optimization of chronic lymphocytic leukemia by chemo-
and chemoimmunotherapies and their influence on patients´ health-
related quality of life“
- 1998 Doctorate by the Medical Faculty of the Ludwig-
Maximilians-University in Munich
„Signal transduction of the CD30-receptor in Hodgkin cell lines“
- 1990-1997 Study of medicine with medical degree at the Medical Faculty of the
Ludwig-Maximilians-University in Munich

Professional Career:

- Since Jan 2012 Consultant at the Department I for Internal Medicine, University of
Cologne
- 2006 - 2010 Head of the clinical trial unit at the Department I for Internal
Medicine, University of Cologne
- 2006 Recognition of specialisation for Hematology and Medical
Oncology by the medical Council Nordrhein
- 2005 Recognition of specialisation for Internal Medicine by the medical
Council Bavaria
- since 2005 Scientific associate at the Department I for Internal Medicine,
University of Cologne
- 1998 - 2005 Scientific associate at the Department III for Internal Medicine,
Klinikum Großhadern of the Ludwig-Maximilians-University
Munich
- 1997 - 1998 Intern at the Medical Clinic Innenstadt,
Ludwig-Maximilians-University Munich

Memberships:

German society for Hematology and Oncology (DGHO)

German society for Internal Medicine (DGIM)

Competent net malignant lymphoma (KML)

European Hematology Association (EHA)

American Society of Hematology (ASH)

Society of Hematologic Oncology (SOHO)

Additional academic activities:

Since 2020 Advisory Board of the KML

Since 2020 Program committee of the Society of Hematologic
Oncology

Since 2019 Member of the International Workshop on CLL (iwCLL)

Since 2018 Advisory Board of the DGHO

2016 -2019 Member of the Scientific program committee of EHA

Since 2016 Member of the Scientific program committee of DGHO

Since 2015 Member of the committee for promotion of young
researchers by DGIM

Since 2005 Secretary of the German CLL Study Group (GCLLSG)

Awards:

2018 Fritz-Acker foundation, award for contribution in haematology and
oncology

2012 Best habilitation in 2011 by the University of Cologne

Editorial Boards:

Since 2023 Editorial Board of *Leukemia*

2020 – 2022 Associate Editor for *Annals of Hematology*

2018 - 2020 *Lancet Oncology* International Advisory Board

Ad Hoc Reviewer:

Annals of Hematology (until 2019)

Annals of Oncology

Blood
Haematologica
Hemasphere
Journal of Clinical Oncology
Lancet
Lancet Oncology
Leukemia
Leukemia & Lymphoma
New England Journal of Medicine

Research field:

To understand the molecular pathogenesis of chronic lymphocytic leukemia (CLL).
To achieve the cure of CLL by conducting practice-changing, systematic clinical studies.

Clinical trial Activity:

Global PI for IITs of the GCLLSG (sponsor university):

Phase II, national: CLL2G, FRAIL

Phase III national: CLL4, CLL5, CLL6

Phase III international: CLL10, CLL13, RT1, CLL16

Global/Country PI for 21 phase I-III trials (sponsor pharmaceutical company).

Deputy PI or SI in > 100 phase I-III trials (sponsor pharmaceutical company or university)

Leading role in writing guidelines: international (ESMO) and national (S3 guideline CLL)